• 1
    American Cancer Society. Cancer Facts & Figures 2002. Atlanta, Ga; 2002.
  • 2
    Von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American Cancer Society Guideline for early detection of prostate cancer: update 1997. CA Cancer J Clin. 1997;47: 2614.
  • 3
    American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology (Huntingt). 2000;14: 26772, 77–8, 280 passim.
  • 4
    Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: framing the debate. Urology. 1995;46: 213.
  • 5
    Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325: 740.
  • 6
    U.S. Preventive Services Task Force. Screening for prostate cancer: recommendation and rationale. Ann Intern Med. 2002;137: 9156.
  • 7
    Ferrini R, Woolf SH. American College of Preventive Medicine Practice Policy: screening for prostate cancer in American men. Am J Prev Med. 1998;15: 815.
  • 8
    Kassirer JP. Incorporating patients’ preferences into medical decisions. N Engl J Med. 1994;330: 18956.
  • 9
    Cantor SB, Spann SJ, Volk RJ, Cardenas MP, Warren MM. Prostate cancer screening: a decision analysis. J Fam Pract. 1995;41: 3341.
  • 10
    Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA. 1994;272: 77380.
  • 11
    Mold JW, Stein HF. The cascade effect in the clinical care of patients. N Engl J Med. 1986;314: 5124.
  • 12
    Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92: 158292.
  • 13
    Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19: 37507.
  • 14
    Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst. 2002;94: 4307.
  • 15
    Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283: 35460.
  • 16
    Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer. 2000;88: 145463.
  • 17
    Volk RJ, Cantor SB, Spann SJ, Cass AR, Cardenas MP, Warren MM. Preferences of husbands and wives for prostate cancer screening. Arch Fam Med. 1997;6: 726.
  • 18
    Boehmer U, Clark JA. Married couples’ perspectives on prostate cancer diagnosis and treatment decision-making. Psychooncology. 2001;10: 14755.
  • 19
    Boehmer U, Clark JA. Communication about prostate cancer between men and their wives. J Fam Pract. 2001;50: 22631.
  • 20
    Cliff AM, MacDonagh RP. Psychosocial morbidity in prostate cancer. II. A comparison of patients and partners. BJU Int. 2000;86: 8349.
  • 21
    Gold MR, Patrick DL. Identifying and valuing outcomes. In: GoldMR, SiegelJE, RussellLB, WeinsteinMC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996: 82134.
  • 22
    Sox HC Jr, Blatt MA, Higgins MC, Marton KI. Medical Decision Making. Boston, Mass: Butterworths; 1988.
  • 23
    Torrance GW. Utility approach to measuring health related quality of life. J Chronic Dis. 1987;40: 593600.
  • 24
    Krahn M, Ritvo P, Irvine J, et al. Construction of the Patient-Oriented Prostate Utility Scale (PORPUS): a multiattribute health state classification system for prostate cancer. J Clin Epidemiol. 2000;53: 92030.
  • 25
    Litwin MS, Melmed GY, Nakazon T. Life after radical prostatectomy: a longitudinal study. J Urol. 2001;166: 58792.
  • 26
    Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 3—estimating probabilities and utilities. Med Decis Making. 1997;17: 13641.
  • 27
    National Center for Health Statistics. Vital Statistics of the United States, 1988. Vol. 2,Part A. Washington, DC: U.S. Department of Health and Human Services, Public Health Service; 1991, Publication PHS 91 1101.
  • 28
    Nease RF Jr, Kneeland T, O'Connor GT, et al. and the Ischemic Heart Disease Patient Outcomes Research Team. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. JAMA. 1995;273: 118590.
  • 29
    Siegel S, Castellan NJ Jr. Nonparametric Statistics for the Behavioral Sciences. New York, NY: McGraw-Hill, Inc.; 1988.
  • 30
    Statistical Package for the Social Sciences. 11.0.1 ed. Chicago, Ill: SPSS, Inc.; 2001.
  • 31
    Smith DS, Krygiel J, Nease RF Jr, Sumner WII, Catalona WJ. Patient preferences for outcomes associated with surgical management of prostate cancer. J Urol. 2002;167: 211722.
  • 32
    Albertsen PC, Nease RF Jr, Potosky AL. Assessment of patient preferences among men with prostate cancer. J Urol. 1998;159: 15863.
  • 33
    Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41: 15364.
  • 34
    Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36: 100212.
  • 35
    Litwin MS, Nied RJ, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med. 1998;13: 15966.
  • 36
    Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function—the most important disease-specific distress for patients with prostate cancer. Br J Cancer. 1996;73: 141721.
  • 37
    Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R. Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol. 1991;9: 32834.
  • 38
    O'Rourke ME. Narrowing the options: the process of deciding on prostate cancer treatment. Cancer Invest. 1999;17: 34959.
  • 39
    Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer. 1994;73: 2791802.
  • 40
    Northouse LL, Mood D, Templin T, Mellon S, George T. Couples’ patterns of adjustment to colon cancer. Soc Sci Med. 2000;50: 27184.
  • 41
    Ptacek JT, Pierce GR, Ptacek JJ, Nogel C. Stress and coping processes in men with prostate cancer: the divergent views of husbands and wives. J Soc Clin Psychol. 1999;18: 299324.
  • 42
    Carlson LE, Ottenbreit N, St Pierre M, Bultz BD. Partner understanding of the breast and prostate cancer experience. Cancer Nurs. 2001;24: 2319.
  • 43
    Harvei S, Kravdal O. The importance of marital and socioeconomic status in incidence and survival of prostate cancer. An analysis of complete Norwegian birth cohorts. Prev Med. 1997;26(5 Part 1): 62332.
  • 44
    Bennett CL, Chapman G, Elstein AS, et al. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol. 1997;32(suppl 3):868.
  • 45
    Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC. Preferences for health outcomes: comparison of assessment methods. Med Decis Making. 1984;4: 31529.
  • 46
    Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision making? Arch Intern Med. 1996;156: 141420.
  • 47
    O'Connor AM, Fiset V, DeGrasse C, et al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr. 1999;25: 6780.